Diaceutics Appoints Julie Goonewardene Chair of Its Advisory Board | Diaceutics

Diaceutics Appoints Julie Goonewardene Chair of Its Advisory Board

Diaceutics, a leading international consulting, software and service solutions company, which helps the pharmaceutical and diagnostic industries understand how to make the personalized medicine business model work for all stakeholders, has appointed Julie Goonewardene as Chairwoman of its Board of Advisors

Ms. Goonewardene is currently President of KUIC and Associate Vice Chancellor for Innovation and Entrepreneurship University of Kansas, and has a track record as an experienced entrepreneur, having co-founded and served as president and CEO of Cantilever Technologies, a venture-backed software company that was successfully acquired. Cantilever’s customers were Fortune 500 companies. Prior to Cantilever, she was president of the Strategic Systems Group (SSG), a boutique information technology consulting firm, and co-founder of Technology Solutions (TSC), a professional IT services firm which went public three years after its inception.

“I am personally delighted to have Julie come on board to help us navigate these important next few years,” said Peter Keeling, Chief Executive Officer of Diaceutics. “Like the personalized medicine business area, Diaceutics itself is undergoing tremendous transformation and growth and Julie’s experience with fast moving technology and companies in the healthcare arena is critical to our next stage of development.”

In addition to her role at KU, Ms. Goonewardene is an author, frequent speaker and consultant on entrepreneurship and innovation. Based on success in these areas, Julie was elected to the Board of Trustees for the American Medical Association (AMA), the Board of Directors of the Personalized Medicine Coalition and Matrix-Bio. As a first generation American born to Sri Lankan and Australian parents, she brings a unique global perspective to her endeavours.

Meeting the needs of personalized medicine is a significant challenge for many in the pharmaceutical and diagnostic industries. Diaceutics is building on its eight years of pioneering leadership in the area to expand its innovative services to this client base, recently adding a laboratory services arm and communications and branding services in partnership with Omnicom.

“Diaceutics is a company in the right place at the right time and I am delighted to help the management team manage this crucial next stage of corporate development,” said Ms. Goonewardene.

Julie takes over from Tiffany Olson, the company’s outgoing chairwoman who has resigned to focus on her new role as President, Nuclear Pharmacy Solutions at Cardinal Health.   “We appreciate the invaluable advice and guidance provided by Tiffany  Over the past two years and wish her well in her new role at Cardinal Health,” said Keeling.

Diaceutics is a data analytics and implementation services business for major pharmaceutical companies. The company is transforming an industry model by enabling pharma to accelerate their market penetration and achieve a better return on new therapies by helping them to revolutionise their patient testing. It does this by providing insights generated from its vast data lake consisting of real time diagnostic testing data gather from clinical laboratories around the world. Diaceutics’ services help pharma to understand and leverage the diagnostic landscape and deploy initiatives that improve patient diagnosis. The company has experience of more than 300 precision medicine projects and works with 33 of the world’s top 35 pharmaceutical companies. The company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.

Media Contact
Helen Morrogh
Tel: +353 1 215 7675
Email: helen@comit.ie
For more information, visit www.diaceutics.com or follow Diaceutics on Twitter, LinkedIn or Facebook

Latest Blogs

Latest Blogs